These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 25808097)

  • 1. Pyruvate Kinase M2 Modulates Esophageal Squamous Cell Carcinoma Chemotherapy Response by Regulating the Pentose Phosphate Pathway.
    Fukuda S; Miyata H; Miyazaki Y; Makino T; Takahashi T; Kurokawa Y; Yamasaki M; Nakajima K; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1461-8. PubMed ID: 25808097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
    Papadaki C; Sfakianaki M; Lagoudaki E; Giagkas G; Ioannidis G; Trypaki M; Tsakalaki E; Voutsina A; Koutsopoulos A; Mavroudis D; Georgoulias V; Souglakos J
    Br J Cancer; 2014 Oct; 111(9):1757-64. PubMed ID: 25233397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
    Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
    Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.
    Martin SP; Fako V; Dang H; Dominguez DA; Khatib S; Ma L; Wang H; Zheng W; Wang XW
    J Exp Clin Cancer Res; 2020 Jun; 39(1):99. PubMed ID: 32487192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
    PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PKM2 Promotes Cell Survival and Invasion Under Metabolic Stress by Enhancing Warburg Effect in Pancreatic Ductal Adenocarcinoma.
    Li C; Zhao Z; Zhou Z; Liu R
    Dig Dis Sci; 2016 Mar; 61(3):767-73. PubMed ID: 26500118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyruvate kinase M2 prevents apoptosis via modulating Bim stability and associates with poor outcome in hepatocellular carcinoma.
    Hu W; Lu SX; Li M; Zhang C; Liu LL; Fu J; Jin JT; Luo RZ; Zhang CZ; Yun JP
    Oncotarget; 2015 Mar; 6(9):6570-83. PubMed ID: 25788265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutually exclusive mutations in NOTCH1 and PIK3CA associated with clinical prognosis and chemotherapy responses of esophageal squamous cell carcinoma in China.
    Song B; Cui H; Li Y; Cheng C; Yang B; Wang F; Kong P; Li H; Zhang L; Jia Z; Bi Y; Wang J; Zhou Y; Liu J; Wang J; Zhao Z; Zhang Y; Hu X; Shi R; Yang J; Liu H; Yan T; Li Y; Xu E; Qian Y; Xi Y; Guo S; Chen Y; Wang J; Li G; Liang J; Jia J; Chen X; Guo J; Wang T; Zhang Y; Li Q; Wang C; Cheng X; Zhan Q; Cui Y
    Oncotarget; 2016 Jan; 7(3):3599-613. PubMed ID: 26528858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma.
    Liu WR; Tian MX; Yang LX; Lin YL; Jin L; Ding ZB; Shen YH; Peng YF; Gao DM; Zhou J; Qiu SJ; Dai Z; He R; Fan J; Shi YH
    Oncotarget; 2015 Jan; 6(2):846-61. PubMed ID: 25514599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyruvate kinase M2 is highly correlated with the differentiation and the prognosis of esophageal squamous cell cancer.
    Zhan C; Shi Y; Lu C; Wang Q
    Dis Esophagus; 2013; 26(7):746-53. PubMed ID: 23317289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.
    Shen LY; Wang H; Dong B; Yan WP; Lin Y; Shi Q; Chen KN
    Oncotarget; 2016 Jan; 7(4):4531-41. PubMed ID: 26673820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
    Kim DJ; Park YS; Kang MG; You YM; Jung Y; Koo H; Kim JA; Kim MJ; Hong SM; Lee KB; Jang JJ; Park KC; Yeom YI
    Exp Cell Res; 2015 Aug; 336(1):119-29. PubMed ID: 26112218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of pyruvate kinase M2 isoform inhibits cell motility in hepatocellular carcinoma cells.
    Chen YL; Song JJ; Chen XC; Xu W; Zhi Q; Liu YP; Xu HZ; Pan JS; Ren JL; Guleng B
    World J Gastroenterol; 2015 Aug; 21(30):9093-102. PubMed ID: 26290635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PITX2: a promising predictive biomarker of patients' prognosis and chemoradioresistance in esophageal squamous cell carcinoma.
    Zhang JX; Tong ZT; Yang L; Wang F; Chai HP; Zhang F; Xie MR; Zhang AL; Wu LM; Hong H; Yin L; Wang H; Wang HY; Zhao Y
    Int J Cancer; 2013 Jun; 132(11):2567-77. PubMed ID: 23132660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM, a potential therapeutic target for esophageal squamous cell carcinoma.
    Matsuda T; Takeuchi H; Matsuda S; Hiraiwa K; Miyasho T; Okamoto M; Kawasako K; Nakamura R; Takahashi T; Wada N; Kawakubo H; Saikawa Y; Omori T; Kitagawa Y
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S356-64. PubMed ID: 24566863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of pyruvate kinase M2 associates with aggressive clinicopathological features and unfavorable prognosis in oral squamous cell carcinoma.
    Wang Y; Zhang X; Zhang Y; Zhu Y; Yuan C; Qi B; Zhang W; Wang D; Ding X; Wu H; Cheng J
    Cancer Biol Ther; 2015; 16(6):839-45. PubMed ID: 25970228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The responsively decreased PKM2 facilitates the survival of pancreatic cancer cells in hypoglucose.
    Li X; Deng S; Liu M; Jin Y; Zhu S; Deng S; Chen J; He C; Qin Q; Wang C; Zhao G
    Cell Death Dis; 2018 Jan; 9(2):133. PubMed ID: 29374159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moderate DNA damage promotes metabolic flux into PPP via PKM2 Y-105 phosphorylation: a feature that favours cancer cells.
    Kumar B; Bamezai RN
    Mol Biol Rep; 2015 Aug; 42(8):1317-21. PubMed ID: 25840825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mTOR Pathway Regulates PKM2 to Affect Glycolysis in Esophageal Squamous Cell Carcinoma.
    Xiaoyu H; Yiru Y; Shuisheng S; Keyan C; Zixing Y; Shanglin C; Yuan W; Dongming C; Wangliang Z; Xudong B; Jie M
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818780063. PubMed ID: 29916308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. M2 isoform of pyruvate kinase (PKM2) is upregulated in Kazakh's ESCC and promotes proliferation and migration of ESCC cells.
    Liu Q; Liang M; Liu T; Vuitton L; Zheng S; Gao X; Lu M; Li X; Sheyhidin I; Lu X
    Tumour Biol; 2016 Feb; 37(2):2665-72. PubMed ID: 26404132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.